CD8A and neoplasm: Indeed, Batf3-dependent cDC1s are needed to mount anti-tumor CD8+ T cell responses at baseline [25] or upon poly I:C therapy [27] and are indispensable for efficacy of immune checkpoint blockade [28, 29].